CN108478855A - A kind of bleeding-stopping dressing - Google Patents
A kind of bleeding-stopping dressing Download PDFInfo
- Publication number
- CN108478855A CN108478855A CN201810460000.8A CN201810460000A CN108478855A CN 108478855 A CN108478855 A CN 108478855A CN 201810460000 A CN201810460000 A CN 201810460000A CN 108478855 A CN108478855 A CN 108478855A
- Authority
- CN
- China
- Prior art keywords
- bleeding
- parts
- dressing
- stopping dressing
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000001110 calcium chloride Substances 0.000 claims abstract description 14
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 15
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 15
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 14
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 14
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 230000023555 blood coagulation Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000000855 fungicidal effect Effects 0.000 claims description 7
- 239000000417 fungicide Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 2
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000004280 Sodium formate Substances 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- WQPDQJCBHQPNCZ-UHFFFAOYSA-N cyclohexa-2,4-dien-1-one Chemical compound O=C1CC=CC=C1 WQPDQJCBHQPNCZ-UHFFFAOYSA-N 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims 1
- 235000019254 sodium formate Nutrition 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000000025 haemostatic effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 230000002745 absorbent Effects 0.000 abstract description 2
- 239000002250 absorbent Substances 0.000 abstract description 2
- 229920006037 cross link polymer Polymers 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 208000032843 Hemorrhage Diseases 0.000 description 23
- 230000000740 bleeding effect Effects 0.000 description 16
- 239000000463 material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of bleeding-stopping dressings, by absorbent gelling crosslinked polymer sodium carboxymethylcellulose wound blood is absorbed in wound, sticky spawn can be formed, styptic powder sticking in wound is increased, chitosan not only plays the role of sterilization, also has the function of enhancing gel-forming, and the addition for passing through calcium chloride, the hemostatic function of composition is further enhanced, the composition manufacturing cost is low, and haemostatic effect is excellent.
Description
Technical field
This application involves field of pharmaceutical preparations more particularly to a kind of bleeding-stopping dressing fields.
Background technology
It is one of dead most important reason of the war wound wounded to lose blood, and is generally divided into internal bleeding and external bleeding, goes out in vivo
Blood is mostly due to Viscera rupture, and external bleeding is substantially damaged due to arteriovenous, and dressing is as hemostatic material, refers to lid
On wound, there is the covering of protective effect, control bleeding can be assisted, prevent from infecting and absorbing secretion, bleeding-stopping dressing pair
It has great significance in timely hemostasis.
Traditional hemostatic material is generally divided into following several classes：Traditional cotton fabric material, biological medical polymer material, people
The dressing of work fibrin, minerals dressing, liquid type dressing, metal class dressing, wherein traditional cotton goods dressing is as hemostatic material
Material, refers to the covering for covering on wound, having protective effect, can assist control bleeding, prevent from infecting and absorbing secretion, only
Blood dressing has great significance for stopping blooding in time, but only plays physical protection to the surface of a wound, without coagulation factor, and is easy
It is adhered the surface of a wound；High molecular material is generally divided into natural polymer and synthesis high molecular material, using this material to local stimulation
It is smaller, but haemostatic effect is often poor；The haemostatic effect of artificial fiber albumen dressing is excellent, but manufacturing cost is higher；Mineral
Matter dressing, liquid type dressing, the dressing of metal class, which have the hemostasis of internal wound, applies upper limitation.
Invention content
In order to solve the problems in the existing technology, the present invention provides a kind of bleeding-stopping dressing, which is powdery group
Close object, characterized in that the polymer containing water absorption and swelling, fungicide, rush blood coagulation substance in composition.
Further, the polymer of water absorption and swelling is croscarmellose sodium；
Further, fungicide is selected from chitosan；
Further, promote blood coagulation substance and be selected from calcium chloride, fibrinogen, vitamin K, collagen, fibronectin, blood coagulation
One or more of factor combines；
Further, preservative, filler are contained in composition；
Further, the one kind or several of preservative in methyl hydroxybenzoate, ethyl hydroxy benzoate, sodium benzoate, dimethyl fumarate
Kind combination；
Further, filler is selected from talcum powder, starch, lactose, calcium carbonate, dextrin, microcrystalline cellulose；
Invention further provides a kind of bleeding-stopping dressings, it is characterised in that：The dressing is powder composition, in composition
Contain following components by weight percent substance：20-50 parts of croscarmellose sodium, promotees 1 part of blood coagulation substance at 15-45 parts of fungicide.
Further, following parts by weight of component substance is contained in composition：20-50 parts of croscarmellose sodium, sterilization
15-45 parts of agent promotees 1 part of blood coagulation substance, 2 parts of methyl hydroxybenzoate, 16 parts of talcum powder, 16 parts of lactose；
Further, change dressing and contain following parts by weight of component：50 parts of croscarmellose sodium, 15 parts of chitosan, chlorine
Change 1 part of calcium, 2 parts of methyl hydroxybenzoate, 16 parts of talcum powder, 16 parts of lactose.
Invention further provides a kind of preparation methods of bleeding-stopping dressing, it is characterised in that：By cross-linked carboxymethyl fiber
Plain sodium, calcium chloride, lactose are added in suitable quantity of water, and heating makes to be completely dissolved, and obtain solution A, and methyl hydroxybenzoate, which is dissolved in ethyl alcohol, obtains solution
Solution B is slowly added into solution A by B under agitation, continues to stir, and chitosan is added, and high speed shear 2 hours obtains
Mixed liquor C is freeze-dried to obtain uniformly powdered dressing by mixed liquor C.
The beneficial effects of the invention are as follows：
The present invention absorbs wound blood by absorbent gelling crosslinked polymer sodium carboxymethylcellulose in wound, can be formed
Sticky spawn increases styptic powder sticking in wound, and chitosan not only plays the role of sterilization,
Have the function of enhancing gel-forming, and by the addition of calcium chloride, further enhances the hemostatic function of composition, the combination
Object manufacturing cost is low, and haemostatic effect is excellent.
Specific implementation mode
With reference to embodiment, the present invention is described in further detail, but protection scope of the present invention is not limited to this.
Embodiment 1
Croscarmellose sodium 50%, chitosan 15%, calcium chloride 1%, methyl hydroxybenzoate 2%, talcum powder 16%, breast
Sugar 16%；
Preparation method：Croscarmellose sodium, calcium chloride, lactose are added in suitable quantity of water, heating makes completely molten
Solution, obtains solution A, methyl hydroxybenzoate be dissolved in ethyl alcohol solution B is slowly added into solution A by solution B under agitation, after
Continuous stirring, is added chitosan, and high speed shear 2 hours obtains mixed liquor C, is freeze-dried uniformly powdered deposited by mixed liquor C
Material.
Embodiment 2
Croscarmellose sodium 35%, chitosan 30%, calcium chloride 1%, methyl hydroxybenzoate 2%, talcum powder 16%, breast
Sugar 16%；
The preparation method is the same as that of Example 1.
Embodiment 3
Croscarmellose sodium 20%, chitosan 45%, calcium chloride 1%, methyl hydroxybenzoate 2%, talcum powder 16%, breast
Sugar 16%；
The preparation method is the same as that of Example 1.
Embodiment 4
Croscarmellose sodium 15%, chitosan 50%, calcium chloride 1%, methyl hydroxybenzoate 2%, talcum powder 16%, breast
Sugar 16%；
The preparation method is the same as that of Example 1.
Embodiment 5
Croscarmellose sodium 65%, calcium chloride 1%, methyl hydroxybenzoate 2%, talcum powder 16%, lactose 16%；
The preparation method is the same as that of Example 1.
Embodiment 6
Croscarmellose sodium 51%, chitosan 15%, methyl hydroxybenzoate 2%, talcum powder 16%, lactose 16%；
The preparation method is the same as that of Example 1.
The hemostasis of rats'liver Hemorrhage Model is tested
Rat is grouped at random, every group 6, respectively positive controls (He Xueting) and experimental group, the injection of each group rat
10% chloraldurate 1mL anesthesia, cuts abdominal muscle, squeezes out liver organ, blot liver surrounding liquid, the gauze after drop is weighed is padded on
Under liver, the liver middle period is quickly cut off in each experimental group liver lower edge same location, uniformly smears equivalent positive drug and experimental drug
Object is in incision, and timing to stopped bleeding, with the exudation of no bright red blood to stop bleeding standard, observation each group obtains blood clotting situation,
Amount of bleeding and bleeding stopping period are recorded, amount of bleeding is in terms of gauze weightening, and the bleeding time, each group obtained to cut off the liver middle period to stopped bleeding
Haemostatic effect is as follows：
According to above-mentioned experimental data it is found that the bleeding time of 1-3 each group compositions of the embodiment of the present invention and amount of bleeding and sun
Property control group compare, all have more significant shortening and reduction, embodiment 4 has extended bleeding time and amount of bleeding, this may
With the reduction of croscarmellose sodium dosage, absorption liquid ability is caused to decline related, and then powder is in the non-shape in wound
At firm hemostasis gel, and the removal of chitosan and the removal of calcium chloride result in being remarkably decreased for hemostatic capability, show
The two plays important hemostatic function in combination.
Claims (10)
1. a kind of bleeding-stopping dressing, which is characterized in that the dressing is powder composition, the polymerization containing water absorption and swelling in composition
Object, promotees blood coagulation substance at fungicide.
2. bleeding-stopping dressing as described in claim 1, which is characterized in that the polymer of the water absorption and swelling is that cross-linked carboxymethyl is fine
The plain sodium of dimension.
3. bleeding-stopping dressing as described in claim 1, which is characterized in that the fungicide is selected from chitosan.
4. bleeding-stopping dressing as described in claim 1, which is characterized in that the rush blood coagulation substance is selected from calcium chloride, fibrin
One or more of original, vitamin K, collagen, fibronectin, coagulation factor combine.
5. bleeding-stopping dressing as described in claim 1, which is characterized in that further contain preservative, filler in composition.
6. bleeding-stopping dressing as claimed in claim 5, which is characterized in that the preservative is selected from methyl hydroxybenzoate, ethyl hydroxy benzoate, benzene
One or more of sodium formate, dimethyl fumarate combine, filler be selected from talcum powder, starch, lactose, calcium carbonate, dextrin,
One or more of microcrystalline cellulose combines.
7. a kind of bleeding-stopping dressing, which is characterized in that the dressing is powder composition, contains following components by weight percent object in composition
Matter：20-50 parts of croscarmellose sodium, promotees 1 part of blood coagulation substance at 15-45 parts of fungicide.
8. bleeding-stopping dressing as claimed in claim 7, which is characterized in that contain following parts by weight of component object in the composition
Matter：20-50 parts of croscarmellose sodium, promotees 1 part of blood coagulation substance, 2 parts of methyl hydroxybenzoate, talcum powder 16 at 15-45 parts of fungicide
Part, 16 parts of lactose.
9. bleeding-stopping dressing as claimed in claim 7, which is characterized in that the dressing contains following parts by weight of component：It is crosslinked carboxylic
50 parts of sodium carboxymethylcellulose pyce, 15 parts of chitosan, 1 part of calcium chloride, 2 parts of methyl hydroxybenzoate, 16 parts of talcum powder, 16 parts of lactose.
10. a kind of preparation method of bleeding-stopping dressing as claimed in claim 8, which is characterized in that by cross-linked carboxymethyl cellulose
Sodium, calcium chloride, lactose are added in suitable quantity of water, and heating makes to be completely dissolved, and obtain solution A, and methyl hydroxybenzoate, which is dissolved in ethyl alcohol, obtains solution B,
Under agitation, solution B is slowly added into solution A, continues to stir, chitosan is added, high speed shear 2 hours obtains mixed
Liquid C is closed, mixed liquor C is freeze-dried to obtain uniformly powdered dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810460000.8A CN108478855A (en) | 2018-05-15 | 2018-05-15 | A kind of bleeding-stopping dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810460000.8A CN108478855A (en) | 2018-05-15 | 2018-05-15 | A kind of bleeding-stopping dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108478855A true CN108478855A (en) | 2018-09-04 |
Family
ID=63354431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810460000.8A Pending CN108478855A (en) | 2018-05-15 | 2018-05-15 | A kind of bleeding-stopping dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108478855A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125795A (en) * | 2018-10-18 | 2019-01-04 | 赛克赛斯生物科技股份有限公司 | A kind of polysaccharide hemostatic composition and the preparation method and application thereof |
| CN109395143A (en) * | 2018-10-16 | 2019-03-01 | 广州润虹医药科技股份有限公司 | A kind of antiseptic anti-adhesion hydrocolloid oil yarn and preparation method thereof |
| CN111840632A (en) * | 2019-04-25 | 2020-10-30 | 广东泰宝医疗科技股份有限公司 | Liquid dressing containing hemostatic microcapsule and preparation method thereof |
| CN115212349A (en) * | 2022-07-05 | 2022-10-21 | 浦易(上海)生物技术股份有限公司 | Gelable compositions, methods of preparation and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908652A (en) * | 2012-11-07 | 2013-02-06 | 中国人民解放军第二军医大学 | Composite hemostatic material mainly used for emergency aid |
| US20140099374A1 (en) * | 2009-10-06 | 2014-04-10 | Regents Of The University Of Minnesota | Bioresorbable embolization microspheres |
| CN105920658A (en) * | 2016-04-23 | 2016-09-07 | 厦门凝赋生物科技有限公司 | Porous styptic powder and preparation method thereof |
| CN106178088A (en) * | 2016-08-16 | 2016-12-07 | 江苏海泽医疗科技发展有限公司 | A kind of preparation method of styptic powder |
| CN107243086A (en) * | 2017-06-06 | 2017-10-13 | 广西达庆生物科技股份有限公司 | A kind of absorbable compound hemostatic powder and preparation method thereof |
| CN107708751A (en) * | 2015-06-26 | 2018-02-16 | 韩国生产技术研究院 | Medical fibre structure comprising calcium carboxymethylcellulose and chitosan compound and preparation method thereof |
-
2018
- 2018-05-15 CN CN201810460000.8A patent/CN108478855A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140099374A1 (en) * | 2009-10-06 | 2014-04-10 | Regents Of The University Of Minnesota | Bioresorbable embolization microspheres |
| CN102908652A (en) * | 2012-11-07 | 2013-02-06 | 中国人民解放军第二军医大学 | Composite hemostatic material mainly used for emergency aid |
| CN107708751A (en) * | 2015-06-26 | 2018-02-16 | 韩国生产技术研究院 | Medical fibre structure comprising calcium carboxymethylcellulose and chitosan compound and preparation method thereof |
| CN105920658A (en) * | 2016-04-23 | 2016-09-07 | 厦门凝赋生物科技有限公司 | Porous styptic powder and preparation method thereof |
| CN106178088A (en) * | 2016-08-16 | 2016-12-07 | 江苏海泽医疗科技发展有限公司 | A kind of preparation method of styptic powder |
| CN107243086A (en) * | 2017-06-06 | 2017-10-13 | 广西达庆生物科技股份有限公司 | A kind of absorbable compound hemostatic powder and preparation method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109395143A (en) * | 2018-10-16 | 2019-03-01 | 广州润虹医药科技股份有限公司 | A kind of antiseptic anti-adhesion hydrocolloid oil yarn and preparation method thereof |
| CN109395143B (en) * | 2018-10-16 | 2021-06-01 | 广州润虹医药科技股份有限公司 | Antibacterial anti-adhesion hydrocolloid oily yarn and preparation method thereof |
| CN109125795A (en) * | 2018-10-18 | 2019-01-04 | 赛克赛斯生物科技股份有限公司 | A kind of polysaccharide hemostatic composition and the preparation method and application thereof |
| CN109125795B (en) * | 2018-10-18 | 2021-06-15 | 赛克赛斯生物科技股份有限公司 | Polysaccharide hemostatic composition and preparation method and application thereof |
| CN111840632A (en) * | 2019-04-25 | 2020-10-30 | 广东泰宝医疗科技股份有限公司 | Liquid dressing containing hemostatic microcapsule and preparation method thereof |
| CN115212349A (en) * | 2022-07-05 | 2022-10-21 | 浦易(上海)生物技术股份有限公司 | Gelable compositions, methods of preparation and uses thereof |
| CN115212349B (en) * | 2022-07-05 | 2023-11-21 | 浦易(上海)生物技术股份有限公司 | Gellable composition, method for the production and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230381288A1 (en) | Hemostatic compositions | |
| JP6868314B2 (en) | Wound dressing containing hyaluronic acid-calcium and polylysine and its manufacturing method | |
| CN108478855A (en) | A kind of bleeding-stopping dressing | |
| AU2017310470B2 (en) | Hemostatic flowable | |
| CN106474524A (en) | A kind of degradable starch sthptic sponge and preparation method thereof | |
| GB2447685A (en) | Haemostatic and dentifrice compositions | |
| RU2731371C2 (en) | Haemostatic mixture of short and long cellulose-based fibers | |
| CN105597142A (en) | Medical bio-fiber styptic powder material and preparation method thereof | |
| HK40012180B (en) | Hemostatic compositions | |
| HK40012180A (en) | Hemostatic compositions | |
| CN104491917B (en) | A kind of biomaterial containing PEG or derivatives thereof | |
| HK40012614A (en) | Hemostatic flowable | |
| HK40012614B (en) | Hemostatic flowable | |
| NZ750516B2 (en) | Hemostatic flowable | |
| CN105664233A (en) | Novel hemostatic material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180904 |